Trials soon ready
Clinical trials expected to report results within the next 3 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Showing the top 50 of 87 trials in this window.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread Results expected Sep 2026 (estimated) 🚀 Make-or-breakClarity Pharmaceuticals Ltd ASX: CU6
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-breakSinovac Biotech Co., Ltd. NASDAQ: SVA
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
Can a shorter radiation course spare the rectum in rectal cancer?
Cure OngoingThe hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch\&wait…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Could a Virus-Like particle vaccine outsmart polio?
Vaccine OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
Result impactVery highSmall-cap Phase 2 Readout in ~1 wkA small company. This result carries real weight for it.
CanSino Biologics Inc. · 6185 HKEXWhy investors are watching
CanSino Biologics is testing a new polio vaccine that uses virus-like particles instead of the traditional live or inactivated virus. This trial checks the vaccine's safety and immune response in infants and toddlers, and a positive result could give the small company a new product in a global market with steady demand. Because CanSino is small, this single trial's outcome can meaningfully affect its value and reputation.
If it works: A successful readout could position CanSino as a leader in next-generation polio vaccines, potentially opening partnerships or licensing deals with larger organizations. It may also validate the company's VLP platform for other vaccines, broadening its pipeline.
If it fails: The trial could fail to show adequate immune response or safety, which would set back the program and hurt investor confidence. Trials at this stage often fail, and any delay in enrollment or dosing could also weigh on the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can specially trained immune cells flush out hidden HIV?
Cure OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase 1 • Sponsor: Catherine Bollard • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with leukemia: smarter chemo dosing could boost cures
Cure OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Cure
Last updated Jul 18, 2026 00:00 UTC
-
Can a single radiation dose cure large liver tumors?
Cure Recruiting nowThe RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in pa…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells target CD5 in Hard-to-Treat T-Cell lymphomas
Cure Recruiting nowThis is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in …
Results expected Nov 2026 (estimated)
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Can a Three-Drug cocktail before surgery stop small cell lung cancer from returning?
Cure Recruiting nowThis is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer. Adebrelimab combined with chemotherapy for 4 cycles and apatinib mesylate for 3 cycles. Surgery was perform…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Jin Ying • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingThis is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~2 moA small company. This result carries real weight for it.
Adicet Bio · ACET NASDAQ Trade on eToro (ad)Why investors are watching
Adicet Bio runs this Phase 1/2 trial of ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70, in adults with relapsed or refractory clear cell renal cell carcinoma. The study tests dose escalation and dose expansion across 60 planned participants. For a micro-cap company, this readout carries the whole story: it is the main evidence that the platform works in patients.
If it works: A positive result could support further development of ADI-270 and draw partner or financing interest. It may also validate the company's engineered gamma-delta T cell approach beyond this one cancer.
If it fails: Early-phase trials often fail on safety, tolerability, or signs of benefit. A failure or delay could leave the company with limited clinical momentum and few other late-stage assets.
AI-written from the trial record. Speculative, and not investment advice.
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
Cure Recruiting nowThis is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: New York Medical College • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
Vaccine OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Vaccine
Last updated Jul 08, 2026 00:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
Cure Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
New chikungunya vaccine trial aims to protect millions
Vaccine Recruiting nowA Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: Bharat Biotech International Limited • Aim: Vaccine
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells take aim at Mesothelioma—Can they deliver?
Cure OngoingThis study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an M…
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
Can a Patient's own immune cells beat advanced kidney cancer?
Cure Not yet recruitingA Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and Subsequent Interleukin-2 Therapy in Patients with Advanc…
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
New marburg vaccine trial aims to stop deadly virus
Vaccine OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Results expected Oct 2026 (estimated)
Phase 2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: Vaccine
Last updated Sep 12, 2026 00:00 UTC
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
Vaccine OngoingThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~2 wkA large company. One readout moves the needle only so far.
-
New needle treatment could replace surgery for curing Hormone-Driven high blood pressure
Cure OngoingThe primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Secondary objectives are to …
Results expected Nov 2026 (estimated)
Sponsor: Queen Mary University of London • Aim: Cure
Last updated Jul 19, 2026 00:00 UTC
-
Promising malaria vaccine candidates enter key trial in african children
Vaccine OngoingThis is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 11:01 UTC
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
Vaccine Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
New 24-Valent vaccine aims to shield children from more pneumonia strains
Vaccine Recruiting nowA Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenici…
Results expected Sep 2026 (estimated)
Phase 2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:06 UTC
Result impactVery highSmall-cap Phase 2 Readout dueA small company. This result carries real weight for it.
Sinovac Biotech Ltd. · SVA NASDAQWhy investors are watching
Sinovac Biotech Ltd. is a small publicly traded company, and its unit Sinovac Life Sciences Co., Ltd. runs this Phase 2 trial of a 24-valent pneumococcal conjugate vaccine in children aged 2 months to 5 years. The trial tests whether the vaccine is safe and produces an immune response, comparing it against an existing positive control in 420 participants. For a company this size, a vaccine that covers more pneumococcal strains than current options would matter because pediatric vaccines sell in large, recurring public health markets.
If it works: If the vaccine proves safe and immunogenic, Sinovac could move it into later-stage trials and toward a product that competes in the pediatric pneumococcal vaccine market. A strong result may also draw partner or public health interest that a small company cannot generate on its own.
If it fails: Phase 2 trials often fail on safety or immune response, and a negative readout would end this program's path forward. A delay or weak result would cost the company time and money it may struggle to replace at its size.
AI-written from the trial record. Speculative, and not investment advice.
-
New RSV vaccine trial aims to protect vulnerable transplant recipients
Vaccine OngoingAdjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral an…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Vaccine
Last updated Jun 27, 2026 12:28 UTC
-
New vaccines aim to block malaria transmission in africa
Vaccine OngoingAssessing the safety, immunogenicity and ex-vivo efficacy of two transmission blocking vaccines (Pfs25-IMX313 in Matrix M and Pfs48/45 in Matrix M alone and co-administered) in Burkina Faso, in 18-45 years, 12-17 years and 05-11 year olds.
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 09:08 UTC
-
New vaccine aims to shield against deadly meningitis strains
Vaccine Recruiting nowPhase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: EyeGene Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:00 UTC
-
Cancer vaccine aims to prevent leukemia relapse in older adults
Vaccine OngoingThis research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Results expected Sep 2026 (estimated)
Phase 2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Vaccine
Last updated Jun 27, 2026 09:01 UTC
-
New shingles vaccine trial aims to protect millions over 40
Vaccine OngoingThe objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Ab&B Bio-tech Co., Ltd.JS • Aim: Vaccine
Last updated Jun 27, 2026 12:01 UTC
-
MRNA technology takes on the stomach flu: moderna launches norovirus vaccine trial
Vaccine OngoingThe purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate …
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:03 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~1 wkA large company. One readout moves the needle only so far.
-
New malaria vaccine trial aims to block infection without causing illness
Vaccine Recruiting nowThis is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy, malaria-naive study participants in Germany by direct ven…
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Sanaria Inc. • Aim: Vaccine
Last updated Jun 27, 2026 14:01 UTC
-
RSV booster study aims to keep seniors safe for five seasons
Vaccine OngoingThe purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vac…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jul 31, 2026 00:00 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactHighLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
New malaria vaccine trial aims to block the parasite at multiple stages
Vaccine Recruiting nowThis is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and children aged 5-17 months in Burkina Faso.
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: University of Oxford • Aim: Vaccine
Last updated Jun 27, 2026 11:01 UTC
-
New nasal spray COVID-19 booster could replace needles
Vaccine Recruiting nowThis Phase I/II trial in France evaluates safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine (LVT-001) versus a booster dose of a COVID-19 mRNA vaccine (Pfizer-BioNTech) in healthy adult volunteers. As a first-in-human trial, Phase I will assess the sa…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Vaccine
Last updated Jun 27, 2026 08:05 UTC
-
Could a Freeze-Dried vaccine shield all ages from hib?
Vaccine OngoingThis trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of…
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
Result impactHighSmall-cap Readout in ~1 wkA small company. This result carries real weight for it.
CanSino Biologics Inc. · 6185 HKEXWhy investors are watching
CanSino Biologics is running a phase 1 trial of its Haemophilus influenzae type b (Hib) conjugate vaccine, testing safety and immune response in 160 people across four age groups, from adults down to 2-month-old infants. For a small company, this early-stage readout matters because it is the first test of whether the vaccine is safe enough to keep developing, and a clear safety signal in infants would support moving to larger trials.
If it works: A positive safety result could let CanSino advance the vaccine into later-stage studies, adding a new product to its pipeline and potentially broadening its vaccine portfolio. Success here would also validate the company's ability to run a complex age-tiered trial, which could strengthen its standing with partners or regulators.
If it fails: Phase 1 trials often fail or reveal safety problems, and a poor result in any age group, especially infants, could halt the program and waste the company's resources. Delays in enrolling or confirming safety between age groups could also push back timelines and raise costs for a small-cap company.
AI-written from the trial record. Speculative, and not investment advice.
-
BioNTech launches first human test of mRNA herpes vaccine
Vaccine OngoingThis exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2 genital herpes. Part A will focus on the safety ev…
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
BioNTech SE · BNTX NASDAQ Trade on eToro (ad)Result impactLowLarge company Readout in ~1 wkA large company. One readout moves the needle only so far.
-
Could a Plant-Based vaccine beat the flu?
Vaccine OngoingThis Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: Aramis Biotechnologies Inc. • Aim: Vaccine
Last updated Aug 06, 2026 00:00 UTC
-
Pregnancy vaccine shields newborns from RSV: Real-World data reveals impact
Vaccine OngoingThis study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over multiple seasons, which began in 2024 across Argentina…
Results expected Oct 2026 (estimated)
Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:34 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactLowLarge company Readout in ~1 wkA large company. One readout moves the needle only so far.
-
Could this mRNA vaccine stop the virus behind mono and certain cancers?
Vaccine OngoingThe main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adole…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~2 wkA large company. One readout moves the needle only so far.
-
Moderna launches first human test of mRNA vaccine against Epstein-Barr virus
Vaccine OngoingThe purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactLowLarge company Readout in ~3 wkA large company. One readout moves the needle only so far.
-
New HIV vaccine trial aims to spark rare antibodies that could fight the virus
Vaccine OngoingThis is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 08:11 UTC
-
New meningitis vaccine for kids shows promise in large trial
Vaccine OngoingThe goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years. The main questions it aims to answer are: Is the immune response induced by the investigationa…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
Result impact 🚀 Make-or-breakVery highSmall-cap Phase 3, decisive Readout in ~6 wkA result this decisive could redraw a company this size.
Sinovac Biotech Co., Ltd. · SVA NASDAQWhy investors are watching
Sinovac Biotech is running a Phase 3 trial of its ACYW135 meningococcal conjugate vaccine in children aged 2 to 6 years, comparing it against a licensed control vaccine. For a small-cap vaccine maker, this readout matters because a positive result could expand its pediatric vaccine portfolio and strengthen its competitive position in a market where efficacy and safety data drive adoption.
If it works: If the trial shows the new vaccine is non-inferior to the control and has an acceptable safety profile, Sinovac could gain regulatory support and a new product to sell in a pediatric market. That would give the company a second revenue stream beyond its existing vaccines.
If it fails: If the vaccine fails to match the control's immune response or shows safety problems, Sinovac would likely need to redesign or abandon the program, wasting years of development cost. Trials in this phase often fail, so a negative result is a real possibility that could hurt the company's pipeline value.
AI-written from the trial record. Speculative, and not investment advice.
-
Ebola survivors get vaccine booster to ward off return of the virus
Vaccine OngoingThis study is a vaccine-related clinical trial which will be conducted by our study team at Kenema Government Hospital (KGH)'s Viral Hemorrhagic Fever Program in collaboration with Tulane University School of Medicine. This study is funded by Merck \& Co., the developers of ERVEB…
Results expected Nov 2026 (estimated)
Phase 4 • Sponsor: Tulane University • Aim: Vaccine
Last updated Jun 27, 2026 13:04 UTC
-
New novavax JN.1 vaccine trial aims to protect adults 50-64 from COVID
Vaccine OngoingThis is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for …
Results expected Nov 2026 (estimated)
Phase 4 • Sponsor: Novavax • Aim: Vaccine
Last updated Jun 27, 2026 12:30 UTC
Result impactHighSmall-cap Readout in ~2 moA small company. This result carries real weight for it.
Novavax · NVAX NASDAQ Trade on eToro (ad)Why investors are watching
Novavax is testing its updated JN.1 COVID-19 vaccine in 6,500 adults aged 50 to under 65 without high-risk conditions. This Phase 4 post-marketing study matters because a positive result could support broader use of the vaccine in a large, generally healthy age group, which is important for a small company whose revenue depends on COVID vaccine sales.
If it works: A positive result could strengthen Novavax's position in the adult COVID vaccine market and support future recommendations for this age group. That could help the company maintain a steady revenue stream from its only commercial product.
If it fails: The trial could fail to show the vaccine prevents COVID better than placebo, or safety issues could emerge. Trials fail often, and a negative result would likely hurt Novavax's credibility and sales prospects for this vaccine.
AI-written from the trial record. Speculative, and not investment advice.
-
New 24-Strain pneumonia vaccine enters human trials
Vaccine Recruiting nowThis clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months (minimum 6 weeks) and older.
Results expected Nov 2026 (estimated)
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 07, 2026 00:00 UTC
Result impactVery highSmall-cap Phase 2 Readout in ~2 moA small company. This result carries real weight for it.
CanSino Biologics Inc. · 6185 HKEXWhy investors are watching
CanSino Biologics is testing a 24-valent pneumococcal vaccine in a Phase 1 and Phase 2 trial with 854 participants, ranging from infants to older adults. For a small company, this readout matters because it tests whether the vaccine is safe and triggers an immune response, which could determine if the product advances to later-stage studies.
If it works: A positive result could show the vaccine is safe and immunogenic, potentially allowing CanSino to move it into larger trials. That progress could strengthen the company's pipeline and its position in the pneumococcal vaccine market.
If it fails: The trial could fail to show adequate safety or immune response, or face delays in enrollment or analysis. Trials at this stage often fail, and a negative result would likely set back the program and hurt the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
Mpox vaccine gets a production upgrade: new cell recipe under trial
Vaccine OngoingRandomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: Bavarian Nordic • Aim: Vaccine
Last updated Jun 27, 2026 12:05 UTC
Bavarian Nordic · BVNRY OTCResult impactModerateMid-cap Phase 2 Readout in ~2 moA mid-sized company with other programmes alongside this one.
-
New vaccine aims to protect kids from pneumonia – study underway
Vaccine OngoingThe purpose of this study is to evaluate the safety and immunogenicity of PCV21 versus 20vPCV ( 20-valent pneumococcal conjugate vaccine, Prevnar 20) for catch-up vaccination in infants (7 to 11 MoA-Months of age), toddlers (12 to 23 MoA), and children/adolescents (2 to 5 YoA and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
New vaccine aimed at training immune system to fight advanced breast cancer enters first human tests
Vaccine OngoingThe trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without \[adjuvant\], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: ExpreS2ion Biotechnologies • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
New TB vaccine trial aims to stop infection before it starts
Vaccine OngoingTuberculosis (TB) is an infection caused by bacteria passed from one person to another through the air when an infected person for instance coughs, speaks, or sneezes. This study tests the safety and vaccine-induced immune response of a new preventive TB vaccine called H107e/CAF®…
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Statens Serum Institut • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
-
Could a peptide supercharge COVID-19 vaccines for seniors?
Vaccine Recruiting nowThe goal of this research is to learn more about ZADAXIN® (trade name; thymalfasin generic; Ta1 for short) and determine if Ta1 has any benefit in increasing the immune response to the COVID-19 vaccine. Ta1 has been shown to stimulate the immune system to fight infections. This …
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Vaccine
Last updated Jul 18, 2026 00:00 UTC
-
Breathe in protection: inhaled COVID vaccine trial launches
Vaccine Recruiting nowThe goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the exp…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: McMaster University • Aim: Vaccine
Last updated Jun 27, 2026 08:14 UTC
-
Can a vaccine train the body to fight Parkinson's?
Vaccine Recruiting nowAn unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Tridem Bioscience FlexCo • Aim: Vaccine
Last updated Sep 12, 2026 00:00 UTC
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.